ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

被引：0
作者：
Pahwa, R.
Tanner, C. M.
Hauser, R. A.
Nausieda, P.
Truong, D. D.
Hull, K.
Agarwal, P.
Johnson, R.
Ruby, A. E.
McClure, N. L.
Stempien, M. J.
机构：
来源：
MOVEMENT DISORDERS | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2012
引用
收藏
页码：S663 / S663
页数：1
相关论文
共 45 条
[21]   A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment [J].
Cohen, Jeffrey A. ;
Gudesblatt, Mark ;
Hunter, Samuel F. ;
Thrower, Ben ;
Brown, Theodore ;
Souza-Prien, Cindy ;
Chernoff, David ;
Patni, Rajiv .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) :22-23
[22]   Phase 3 study results assessing the efficacy and safety of ads-5102 (amantadine) extended release capsules in ms patients with walking impairment [J].
Cohen, J. ;
Cameron, M. ;
Goldman, M. ;
Goodman, A. ;
Miller, A. ;
Rollins, A. ;
Johnson, R. ;
Llorens, L. ;
Patni, R. ;
Elfont, R. .
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) :227-228
[23]   Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease [J].
Julia Paik ;
Susan J. Keam .
CNS Drugs, 2018, 32 :797-806
[24]   Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease [J].
Paik, Julia ;
Keam, Susan J. .
CNS DRUGS, 2018, 32 (08) :797-806
[25]   ADS-5102 provided reduction in motor complications in Parkinson's disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2) [J].
Isaacson, S. ;
Pahwa, R. ;
Tanner, C. ;
Fahn, S. ;
Espay, A. ;
Trenkwalder, C. ;
Patni, R. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 :355-355
[26]   A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment [J].
Cohen, Jeffrey A. ;
Cameron, Michelle H. ;
Goldman, Myla D. ;
Goodman, Andrew D. ;
Miller, Aaron E. ;
Rollins, Anne ;
Llorens, Lily ;
Patni, Rajiv ;
Elfont, Robert ;
Johnson, Reed .
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) :817-830
[27]   INROADS: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment [J].
Cameron, Michelle ;
Cohen, Jeffrey ;
Miller, Aaron ;
Goodman, Andrew ;
Goldman, Myla ;
Elfont, Robert ;
Souza-Prien, Cindy ;
Felt, Larissa ;
Patni, Rajiv .
NEUROLOGY, 2019, 92 (15)
[28]   Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study) [J].
Pahwa, Rajesh ;
Tanner, Caroline M. ;
Hauser, Robert A. ;
Sethi, Kapil ;
Isaacson, Stuart ;
Truong, Daniel ;
Struck, Lynn ;
Ruby, April E. ;
McClure, Natalie L. ;
Went, Gregory T. ;
Stempien, Mary Jean .
MOVEMENT DISORDERS, 2015, 30 (06) :788-795
[29]   Among Parkinson's disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials [J].
Hauser, R. A. ;
Chernick, D. ;
Formella, A. .
MOVEMENT DISORDERS, 2020, 35 :S398-S398
[30]   POOLED ANALYSIS OF PHASE 3 STUDIES OF ADS-5102 FOR LEVODOPA-INDUCED DYSKINESIA: A DETAILED REVIEW OF MDS-UPDRS, PART IV (MOTOR COMPLICATIONS) [J].
Tanner, C. ;
Pahwa, R. ;
Elmer, L. ;
Isaacson, S. ;
Johnson, R. ;
Felt, L. ;
Patni, R. .
PARKINSONISM & RELATED DISORDERS, 2018, 46 :E20-E20
12345